galectin therapeutics inc (GALT) Key Developments
Galectin Therapeutics, Inc. - Shareholder/Analyst Call
May 15 15
To discuss the company's pipeline of galectin inhibitor compounds and progress in development of treatments for liver fibrosis and cancer; Annual Shareholder Meeting
Galectin Therapeutics Inc. Reports Open-Label Phase 1 Study with 8 Mg/Kg Dose of GR-MD-02 and 2 mg/kg Dose of Midazolam
May 14 15
Galectin Therapeutics Inc. reported that in an open-label Phase 1 study with 8 mg/kg dose of GR-MD-02 and 2 mg/kg dose of midazolam there was no drug-drug interaction and no serious adverse events or drug-related adverse events were observed. This study was required by the U.S. Food and Drug Administration (FDA) and the primary objective was to determine if single or multiple intravenous (IV) doses of GR-MD-02 affect the pharmacokinetics (PK) of midazolam. The secondary objective was to assess the safety and tolerability of GR-MD-02 when administered concomitantly with midazolam. The lack of a drug interaction in this study will permit Galectin to expand the number of patients eligible for its Phase 2 clinical trial. In addition, should GR-MD-02 be approved for marketing, the success of this study supports a broader patient population for the drug label. The open-label Phase 1 study in normal healthy volunteer subjects tested a single dose of IV midazolam in the absence of GR-MD-02, following a single IV dose of GR-MD-02 and following three weekly IV doses of GR-MD-02. The four dosing periods were spaced one week apart, with midazolam PK determined in dosing periods one, two and four. A total of 17 subjects completed the study and met the primary endpoint of midazolam clearance when administered alone, compared with when administered with single and multiple doses of GR-MD-02. Drug to drug interaction studies are an integral part of understanding how a drug will affect patients who are also on other drugs. With completion of this study, the company does not anticipate further drug-drug interaction studies will be required in the development of GR-MD-02.
Galectin Therapeutics, Inc. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2015
May 11 15
Galectin Therapeutics, Inc. reported consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total operating loss of $4,840,000 compared with $4,844,000 a year ago. Net loss applicable to common stock was $5,074,000 or $0.22 per basic and diluted share compared with $5,408,000 or $0.27 per basic and diluted share a year ago. The decrease in net loss applicable to common stockholders is largely due to a decrease in stock-based compensation expense of $0.7 million partially offset by higher research and development expenses related to clinical programs.
Galectin Therapeutics, Inc. Presents at Red Chip Global Online CEO Conference, Apr-23-2015 02:00 PM
Apr 20 15
Galectin Therapeutics, Inc. Presents at Red Chip Global Online CEO Conference, Apr-23-2015 02:00 PM. Speakers: James C. Czirr, Executive Chairman and Executive Vice President - Business Development.
Galectin Therapeutics, Inc., Annual General Meeting, May 21, 2015
Apr 8 15
Galectin Therapeutics, Inc., Annual General Meeting, May 21, 2015., at 09:00 US Eastern Standard Time. Location: McKenna Long & Aldridge LLP. Agenda: To elect the eight nominees for director to hold office for a one-year term, expiring at the 2016 annual meeting of stockholders; to ratify the selection by the audit committee of the board of directors of McGladrey LLP as independent registered public accounting firm for the fiscal year ending December 31, 2015; to re-approve the material terms of the performance goals under the Galectin Therapeutics, Inc. Amended and Restated 2009 Incentive Compensation Plan; and to conduct any other business properly brought before the meeting.